MBX Biosciences names Steve Hoerter CEO, replacing Kent Hawryluk

MBX Biosciences appointed Steve Hoerter as CEO and Executive Chairman, replacing co-founder Kent Hawryluk. Interim CFO John Smither was named permanent CFO. These leadership changes took effect immediately to support the company's focus on key second-half 2026 pipeline milestones, including the Phase 3 start for canvuparatide.

MBX Biosciences named Executive Chairman Steve Hoerter chairman, CEO, replacing co-founder Kent Hawryluk, who stepped down as president, CEO, director. * Hoerter joined the board in April 2025, became executive chairman in November 2025; previously led Deciphera Pharmaceuticals through its commercial buildout. * Interim CFO John Smither was appointed CFO; he joined in March 2026, previously served as CFO of Arcutis Biotherapeutics. * Changes took effect immediately as the company targets key second-half 2026 pipeline milestones, including a Phase 3 start for canvuparatide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131615PRIMZONEFULLFEED9761375) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

MBX Biosciences named Executive Chairman Steve Hoerter chairman, CEO, replacing co-founder Kent Hawryluk, who stepped down as president, CEO, director. * Hoerter joined the board in April 2025, became executive chairman in November 2025; previously led Deciphera Pharmaceuticals through its commercial buildout. * Interim CFO John Smither was appointed CFO; he joined in March 2026, previously served as CFO of Arcutis Biotherapeutics. * Changes took effect immediately as the company targets key second-half 2026 pipeline milestones, including a Phase 3 start for canvuparatide. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607131615PRIMZONEFULLFEED9761375) on July 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)